AnaptysBio, Inc. (NASDAQ: ANAB) is a Healthcare company (Biotechnology) with a market capitalization of $1.4B. The Maz Rating grades it against the other companies in its sector.
AnaptysBio, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $45.61, AnaptysBio, Inc. trades at 7.1x trailing earnings, 7.0x sales and 65.1x book value, with an EV/EBITDA of 16.0. Over the last twelve months it generated about $192M of revenue and $190M of net income. It runs an operating margin of 34.6% and a net margin of 96.3%. It shows return on equity of 907.0%, return on invested capital of -1014.5% and a free cash flow yield of 2.7%. On the balance sheet: a debt-to-equity ratio of 0.60 and a current ratio of 8.40. Over the past 52 weeks the share price ranged from $22.07 to $72.36, with a beta of 0.51.
AnaptysBio, Inc. does not currently pay a dividend.
23 Wall Street analyst ratings cover the stock: 17 Buy and 6 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.